## Message

From: Deener, Kathleen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=B9A2FF1C086249EA8F6414AFDE8A5E54-DEENER, KATHLEEN]

**Sent**: 4/16/2012 12:52:55 PM

To: Flowers, Lynn [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1a4411c874d041b9a8badfc32b91bd70-Flowers, Lynn]; Cogliano, Vincent

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=51f2736376ac4d32bad2fe7cfef2886b-Cogliano, Vincent]; Winner, Darrell

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=860556f5cd0f4855839907bcc90b2c41-Winner, Darrell]; Clark, Becki

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=a906e07f1cd143b9a3c2ddab813b8140-Clark, Becki]

CC: Corona, Elizabeth [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=18d86fb8269b4557b5d06622b3a941af-Corona, Elizabeth]

Subject: Fw: LRM [AMV-112-168] HHS Testimony on Report on Carcinogens #615585774#

Attachments: AMV168 - NIH carcinogen testimony draft.docx

Probably just FYI, but we can offer comments if we want. I've skimmed the testimony and nothing jumps out at me as needing our comment.

If you do want to provide comments, they are due by 11:00 a.m. tomorrow. Please send to me by COB today and I'll get the information to Bob by 11:00 tomorrow.

## Kacee Deener, MPH

Acting Communications Director / Program and Regulatory Support Lead

National Center for Environmental Assessment | U.S. EPA - ORD (Mail Code 8601P) | 1200 Pennsylvania Ave. NW | Washington, D.C. 20460

(ph) 703.347.8514 I (f) 703.347.8699; deener.kathleen@epa.gov

Physical and overnight delivery address: U.S. EPA North Potomac Yard N-7622 | 2733 S. Crystal Dr. | Arlington, VA 22202

---- Forwarded by Kathleen Deener/DC/USEPA/US on 04/16/2012 08:51 AM -----

From: Robert Fegley/DC/USEPA/US

To: Elizabeth Corona/DC/USEPA/US@EPA, Bob Hetes/RTP/USEPA/US@EPA, Jacqueline

McQueen/DC/USEPA/US@EPA, David Dix/RTP/USEPA/US@EPA

Co: Kathleen Deener/DC/USEPA/US@EPA

Date: 04/16/2012 08:48 AM

Subject: Fw: LRM [AMV-112-168] HHS Testimony on Report on Carcinogens #615585774#

Any comments? If so, please let me know by 11 am tomorrow.

Thanks.

Bob

++++++++++++++++++++

Robert Fegley,

Acting Chief, Program Support Staff

Office of Science Policy

Office of Research and Development

**USEPA** 

Washington DC

202/564-6786

\_\_\_\_\_\_\_

---- Forwarded by Robert Fegley/DC/USEPA/US on 04/16/2012 08:46 AM ----

From: Clara Jones/DC/USEPA/US

To: Robert Fegley/DC/USEPA/US@EPA, Douglas Parsons/DC/USEPA/US@EPA, Robin Kime/DC/USEPA/US@EPA,

Marna McDermott/DC/USEPA/US@EPA, Eileen McMahon/OIG/USEPA/US@EPA

Cc: Megan Maguire/DC/USEPA/US@EPA, Joanne Rodman/DC/USEPA/US@EPA, Joel

Beauvais/DC/USEPA/US@EPA, Nancy Long/OIG/USEPA/US@EPA, Tom Dickerson/DC/USEPA/US@EPA, Steven

Kinberg/DC/USEPA/US@EPA, Christina Moody/DC/USEPA/US@EPA, Laura Gomez/DC/USEPA/US@EPA,

jones.clara@epa.gov

Date: 04/13/2012 04:18 PM

Subject: Fw: LRM [AMV-112-168] HHS Testimony on Report on Carcinogens #615585774#

## DEADLINE: 12:00 NOON -- Tuesday, April 17, 2012

## SUBJECT: LRM [AMV-112-168] HHS Testimony on Report on Carcinogens

Attached please find draft NIH (Birnbaum) testimony on the Report on Carcinogens for a Wednesday, April 25th hearing before the House's 1) Science,

Space, and Technology Subcommittee on Investigations and Oversight; and 2) Small Business Subcommittee on Healthcare and Technology. The six-page

testimony discusses the nature and characteristics of the Report generally (e.g., that it is not regulatory), the process NIH followed (including involvement

of CDC, FDA, EPA, CPSC, and OSHA, and peer review per OMB guidance) for the edition released in June 2011, and preparation for the next edition.

The discussion includes activities by the National Toxicology Program, whose policy members include the agencies noted above along with DOD and

ATSDR. This testimony does not discuss small businesses, but a witness from the Small Business Administration's Office of Advocacy will also appear at the hearing. Please respond by the deadline.

In accordance with OMB Circular A-19, OMB requests the views of your agency on the above subject before advising on its relationship to the program of the President.

Please advise us if this item will affect direct spending or receipts for the purposes of the Statutory Pay-as-You-Go Act of 2010.

Thank you



AMV168 - NIH carcinogen testi...